Get startedLog in
    Picture of Cansino Biologics logo

    6185 — Cansino Biologics Cashflow Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Cansino Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-4071,907-1,184-1,979-381
    Depreciation
    Amortisation
    Non-Cash Items-23.7-13554590065.5
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-70.4154-1,445-106-64.4
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Taxes Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-4692,015-1,888-916-169
    Capital Expenditures-271-1,203-1,075-610-458
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items88.1-1,328-117169462
    Acquisition of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-183-2,531-1,192-4423.96
    Financing Cash Flow Items-20.2591-47.4-70.1-70.7
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities4,9241,560855-7.58-334
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash4,2441,009-2,064-1,345-490